Is ACST stock headed to $6?
ACST stock has declined by more than 50% year to date (YTD), vastly trailing the S&P 500’s return of 26%. Source: Shutterstock Today, Oppenheimer initiated coverage on ACST stock with an “outperform” rating and a price target of $6.
Is acasti Pharma (ACST) a good stock to buy?
Acasti Pharma has received 70.90% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote “Outperform” if you believe ACST will outperform the S&P 500 over the long term.
Is acasti trading in a range?
Acasti trading in a range. Might be good for a short swing trade As per title, looks like it might be heading back up in its range. Already up 20% off the bottom with possibly another 20% to go. Just crossed up over its 20 Day Moving Average which is often a good sign. Buyer beware. Keep your stops tight especially as it nears the top.
Is Acst a good stock to buy?
Acasti Pharma Inc (NASDAQ:ACST) The 1 analysts offering 12-month price forecasts for Acasti Pharma Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +433.22% increase from the last price of 0.94.
What does ACST company do?
Acasti Pharma Inc. (ACST) Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
Who owns Acst stock?
Largest shareholders include Bank Of America Corp /de/, Morgan Stanley, National Bank Of Canada /fi/, Geode Capital Management, Llc, FNCMX - Fidelity Nasdaq Composite Index Fund, Edmond De Rothschild Holding S.a., Sterling Investment Advisors, Ltd., Koshinski Asset Management, Inc., UBS Group AG, and Tower Research ...
Where can I buy Acst stock?
Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
What is the future of Acst stock?
The Wall Street analyst predicted that ACASTI PHARMA's share price could reach $6.00 by Dec 22, 2022. The average ACASTI PHARMA stock price prediction forecasts a potential upside of 512.24% from the current ACST share price of $0.98.
Is Acst doing a reverse split?
Acasti Pharma, Inc. (ACST) will effect a one-for-eight (1-8) reverse split of its common stock. The reverse stock split will become effective on Tuesday, August 31, 2021. In conjunction with the reverse split, the CUSIP number will change to 00430K873.
Why did Acst stock drop today?
Why Shares of Acasti Pharma Slumped Tuesday. Acasti Pharma (NASDAQ: ACST) fell by more than 18% in Tuesday trading. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company.
Should I buy or sell Acasti Pharma stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 1 buy rating for the s...
What is Acasti Pharma's stock price forecast for 2022?
1 brokers have issued 12 month target prices for Acasti Pharma's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Acas...
How has Acasti Pharma's stock performed in 2022?
Acasti Pharma's stock was trading at $1.26 at the start of the year. Since then, ACST shares have decreased by 20.7% and is now trading at $0.9991....
When is Acasti Pharma's next earnings date?
Acasti Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 28th 2022. View our earnings forecast for Acasti P...
How were Acasti Pharma's earnings last quarter?
Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.40) EP...
When did Acasti Pharma's stock split? How did Acasti Pharma's stock split work?
Shares of Acasti Pharma reverse split on Tuesday, August 31st 2021. The 1-8 reverse split was announced on Tuesday, August 31st 2021. The number of...
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the following people: Ms. Janelle D'Alvise , Pres, CEO, Corp. Sec. & Director (Age 66, Pay $428.04k) Dr...
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Matinas BioPharma (MTNB) , Concert Pharmaceuticals (CNCE) , Inozyme Pharma (INZY) , OR...
What other stocks do shareholders of Acasti Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTN...
About Acasti Pharma
Headlines
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.
Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions
Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?
Ideas
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Acasti Pharma stock. View analyst ratings for Acasti Pharma or view top-rated stocks.
Profile
IBS squeeze refer to your resources and follow the trend we got day 1 and day 2 now we should see DAY 3 for a zombie move
Component Grades
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil.
ACST POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ACST Stock Summary
Value is the dimension where ACST ranks best; there it ranks ahead of 33.96% of US stocks.
ACST Valuation Summary
With a price/sales ratio of 454.44, Acasti Pharma Inc has a higher such ratio than 98.91% of stocks in our set.
ACST's Quality Factors
In comparison to the median Healthcare stock, ACST's price/sales ratio is 9231.58% higher, now standing at 354.6.
New Strong Sell Stocks for February 23rd
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
BLITF Stock: 7 Thing to Know About Mobile Gaming Play i3 Interactive as Shares Rocket Today
ARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022
Market Sentiment Around Loss-Making Acasti Pharma Inc. (CVE:ACST)
i3 Interactive (OTCMKTS:BLITF) stock is rising higher on Thursday despite a lack of news from the mobile gambling company. Source: Shutterstock Even without news, we’re seeing heavy trading of BLITF stock today. That has more than 1.5 million of the company’s shares changing hands as of this writing.
Why Shares of Acasti Pharma Slumped Tuesday
With the business potentially at an important milestone, we thought we'd take a closer look at Acasti Pharma Inc.'s...
21 Stocks Moving in Wednesday's Pre-Market Session
Acasti Pharma (NASDAQ: ACST) fell by more than 18% in Tuesday trading. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company.
Acasti Pharma Inc.'s (CVE:ACST) Shift From Loss To Profit
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported partial exercise of underwriter’s over-allotment option. Locust Walk Acquisition Corp. (NASDAQ: LWAC) rose 26.9% to $11.12 in pre-market trading.
10 Best Biotech Penny Stocks to Buy Now
We feel now is a pretty good time to analyse Acasti Pharma Inc.'s ( CVE:ACST ) business as it appears the company may...
Signals & Forecast
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Acasti Pharma stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
Is Acasti Pharma stock A Buy?
Acasti Pharma finds support from accumulated volume at $1.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive as most new trades are buy in Acasti Pharma
Acasti Pharma holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Acasti Pharma
In the last 8 trades there were 1.44 million shares bought . The last trade was done 102 days ago by Canan John who bough 42.1 thousand shares. For the period there is more stocks sold than bought, but the most of the latest transactions are buy. This can indicate renewed interest by the insider, but also stock options expiring
Golden Star Signal
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
